Abstract:Many cancers evade immune surveillance by overexpressing PD-L1. PD-L1 interacted with its receptor PD-1, resulting in reduction of T cell proliferation and activation and thereafter cancer cell death mediated by T-lymphocyte. Understanding the mechanisms that regulate PD-L1 was of vital importance for immune checkpoint blockade therapy (ICBT). Human non-small cell lung cancer cells and 293FT cells were used to investigate the function of USP22 upon PD-L1 and CSN5 by WB, Immunoprecipitation, Immunofluorescence and Flow cytometry analysis. B16-F10 cells were used to explore the role of USP22 on tumorigenesis and T cell cytotoxicity. The relationship between USP22 and PD-L1 expression was investigated by Immunohistochemistry analysis in human non-small cell lung cancer samples. Our data showed that USP22 interacted with PD-L1 and promoted its stability. USP22 deubiquitinated PD-L1 and inhibited its proteasome degradation. Moreover, USP22 also interacted with CSN5 and stabilized CSN5 through deubiquitination. Either USP22 or CSN5 could facilitate the interaction of PD-L1 with the other one. Furthermore, USP22 removed K6, K11, K27, K29, K33 and K63-linked ubiquitin chain of both CSN5 and PD-L1. In addition, USP22 depletion inhibited tumorigenesis and promoted T cell cytotoxicity. Besides, USP22 expression positively correlated with PD-L1 expression in human non-small cell lung cancer samples. Here, we suggested that USP22 is a new regulator for PD-L1. On the one hand, USP22 could directly regulate PD-L1 stability through deubiquitination. On the other hand, USP22 regulated PD-L1 protein level through USP22-CSN5-PD-L1 axis. In addition, USP22 depletion inhibited tumorigenesis and promoted T cell cytotoxicity. Besides, USP22 expression positively correlated with PD-L1 expression in human non-small cell lung cancer samples. Together, we identified a new regulator of PD-L1 and characterized the important role of USP22 in PD-L1 mediated immune evasion. Targeting USP22 might be a new solution to ICBT.

USP22 is a Positive Regulator of NFATc2 on Promoting IL2 Expression.

Ubiquitin-specific peptidase 22 in cancer

The Deubiquitinase USP22 Regulates PD-L1 Degradation in Human Cancer Cells.

Usp2a Negatively Regulates Il-1-And Virus-Induced Nf-B Activation By Deubiquitinating Traf6

USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1

Data from USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity

USP 2 a negatively regulates IL-1 band virus-induced NFk B activation by deubiquitinating TRAF 6

USP2a negatively regulates IL-1β- and virus-induced NF-κB activation by deubiquitinating TRAF6.

USP22 Promotes IRF3 Nuclear Translocation and Antiviral Responses by Deubiquitinating the Importin Protein KPNA2

USP12 promotes CD4+ T cell responses through deubiquitinating and stabilizing BCL10

USP22 Controls Inkt Immunity Through MED1 Suppression of Histone H2A Monoubiquitination

USP22 acts as an oncogene by regulating the stability of cyclooxygenase-2 in non-small cell lung cancer.

Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms

USP22 regulation of cyclooxygenase-2 in non-small cell lung cancer

The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7-H4 in lung adenocarcinoma harboring EGFR-activating mutants

USP12 Positively Regulates M-MDSC Function to Inhibit Antitumour Immunity Through Deubiquitinating and Stabilizing P65.

USP18 inhibits NF-κB and NFAT activation during Th17 differentiation by deubiquitinating the TAK1-TAB1 complex.

Supplementary Figures S1-S8 from USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity

Ubiquitin-specific Protease 22 is a Deubiquitinase of CCNB1

USP22 promotes development of lung adenocarcinoma through ubiquitination and immunosuppression

USP22 transcriptional activity is negatively regulated by the histone deacetylase inhibitor trichostatin A.